Effect of large-scale mass drug administration for malaria on mortality and morbidity in Angumu health zone, Ituri, Democratic Republic of Congo.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
06 Feb 2023
Historique:
received: 23 09 2022
accepted: 24 01 2023
entrez: 7 2 2023
pubmed: 8 2 2023
medline: 9 2 2023
Statut: epublish

Résumé

Angumu health zone in Ituri, Democratic Republic of Congo, is a highly malaria-endemic area with an overburdened health system and hosting internally displaced persons (IDP). The World Health Organization recommends mass drug administration (MDA) for malaria in complex emergencies. Therefore, three MDA rounds were implemented by Ministry of Public Health and Médecins sans Frontières from September 2020 to January 2021 in four health areas selected for epidemiological (high malaria incidence) and logistic reasons. Reported mortality and morbidity were compared in locations where MDA has been performed and locations where it has not. A non-randomized controlled population-based retrospective mortality survey was conducted in March 2021. Two-stage cluster sampling was used in villages; all IDP sites were surveyed with systematic random sampling. The main (mortality rates) and secondary (morbidity) outcomes were estimated and compared between locations where MDA had been conducted and where it had not, using mixed Poisson and binomial regression models respectively. Data was collected for 2554 households and 15470 individuals, of whom 721 died in the 18-month recall period. The under-five mortality rate (U5MR) decreased in the locations where MDA had been implemented from 2.32 [1.48-3.16] "before" the MDA to 1.10 [0.5-1.71] deaths/10,000 children under 5 years/day "after", whereas it remained stable from 2.74 [2.08-3.40] to 2.67 [1.84-3.50] deaths/10,000 children/day in the same time periods in locations where MDA had not been implemented. The U5MR and malaria-specific mortality was significantly higher in non-MDA locations after MDA was implemented (aRR = 2.17 [1.36-3.49] and 2.60 [1.56-4.33], respectively, for all-cause and malaria-specific mortality among children  < 5 years). Morbidity (all age and  < 5 years, all cause or malaria-specific) appeared lower in MDA locations 2.5 months after last round: reported malaria-specific morbidity was 14.7% [11-18] and 25.0% [19-31] in villages and IDP sites where MDA had been implemented, while it was 30.4% [27-33] and 49.3% [45-54] in villages and IDP sites with no MDA. Despite traditional limitations associated with non-randomized controlled retrospective surveys, the documented sharp decrease of under-5 mortality and morbidity shows that MDA has the potential to become an important malaria-control tool in emergency settings. Based on these results, new MDA rounds, along with indoor residual spraying campaigns, have been planned in the health zone in 2022. A set of surveys will be conducted before, during and after these rounds to confirm the effect observed in 2021 and assess its duration.

Sections du résumé

BACKGROUND BACKGROUND
Angumu health zone in Ituri, Democratic Republic of Congo, is a highly malaria-endemic area with an overburdened health system and hosting internally displaced persons (IDP). The World Health Organization recommends mass drug administration (MDA) for malaria in complex emergencies. Therefore, three MDA rounds were implemented by Ministry of Public Health and Médecins sans Frontières from September 2020 to January 2021 in four health areas selected for epidemiological (high malaria incidence) and logistic reasons. Reported mortality and morbidity were compared in locations where MDA has been performed and locations where it has not.
METHODS METHODS
A non-randomized controlled population-based retrospective mortality survey was conducted in March 2021. Two-stage cluster sampling was used in villages; all IDP sites were surveyed with systematic random sampling. The main (mortality rates) and secondary (morbidity) outcomes were estimated and compared between locations where MDA had been conducted and where it had not, using mixed Poisson and binomial regression models respectively.
RESULTS RESULTS
Data was collected for 2554 households and 15470 individuals, of whom 721 died in the 18-month recall period. The under-five mortality rate (U5MR) decreased in the locations where MDA had been implemented from 2.32 [1.48-3.16] "before" the MDA to 1.10 [0.5-1.71] deaths/10,000 children under 5 years/day "after", whereas it remained stable from 2.74 [2.08-3.40] to 2.67 [1.84-3.50] deaths/10,000 children/day in the same time periods in locations where MDA had not been implemented. The U5MR and malaria-specific mortality was significantly higher in non-MDA locations after MDA was implemented (aRR = 2.17 [1.36-3.49] and 2.60 [1.56-4.33], respectively, for all-cause and malaria-specific mortality among children  < 5 years). Morbidity (all age and  < 5 years, all cause or malaria-specific) appeared lower in MDA locations 2.5 months after last round: reported malaria-specific morbidity was 14.7% [11-18] and 25.0% [19-31] in villages and IDP sites where MDA had been implemented, while it was 30.4% [27-33] and 49.3% [45-54] in villages and IDP sites with no MDA.
CONCLUSIONS CONCLUSIONS
Despite traditional limitations associated with non-randomized controlled retrospective surveys, the documented sharp decrease of under-5 mortality and morbidity shows that MDA has the potential to become an important malaria-control tool in emergency settings. Based on these results, new MDA rounds, along with indoor residual spraying campaigns, have been planned in the health zone in 2022. A set of surveys will be conducted before, during and after these rounds to confirm the effect observed in 2021 and assess its duration.

Identifiants

pubmed: 36747229
doi: 10.1186/s12936-023-04469-7
pii: 10.1186/s12936-023-04469-7
pmc: PMC9901819
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Informations de copyright

© 2023. The Author(s).

Références

Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):54-65
pubmed: 32618245
PLoS One. 2016 Aug 31;11(8):e0161311
pubmed: 27580098
Malar J. 2016 Sep 20;15:480
pubmed: 27646649
BMC Med. 2018 Dec 10;16(1):215
pubmed: 30526588
Am J Trop Med Hyg. 2015 Jul;93(1):125-134
pubmed: 26013371

Auteurs

Lise Grout (L)

Epicentre, Geneva, Switzerland. lise.grout@epicentre.msf.org.

Yves Katuala Givo (Y)

Médecins Sans Frontières, Goma, Democratic Republic of Congo.

Trish Newport (T)

Médecins Sans Frontières, Geneva, Switzerland.

Tom Adoum Mahamat (TA)

Médecins Sans Frontières, Goma, Democratic Republic of Congo.

Priscillah Gitahi (P)

Médecins Sans Frontières, Goma, Democratic Republic of Congo.

Jean Jacques Mandagot (JJ)

Médecins Sans Frontières, Goma, Democratic Republic of Congo.

Michel Quere (M)

Médecins Sans Frontières, Geneva, Switzerland.

Sophie Wodon (S)

Médecins Sans Frontières, Geneva, Switzerland.

Iza Ciglenecki (I)

Médecins Sans Frontières, Geneva, Switzerland.

Mathieu Bastard (M)

Epicentre, Geneva, Switzerland.

Francis Baelongandi (F)

Ministry of Health, Bunia, Democratic Republic of Congo.

Louis Tshulo (L)

Ministry of Health, Bunia, Democratic Republic of Congo.

Herman Jakisa Uluba (HJ)

Ministry of Health, Bunia, Democratic Republic of Congo.

Esther Sterk (E)

Médecins Sans Frontières, Geneva, Switzerland.

Etienne Gignoux (E)

Epicentre, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH